Report cover image

U.S. Compounding Pharmacies Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Publisher Global Market Insights
Published Jun 04, 2025
Length 142 Pages
SKU # GMI20190443

Description

U.S. Compounding Pharmacies Market was valued at USD 6 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 10.8 billion by 2034. This growth is driven by the increasing demand for personalized medications, particularly among pediatric and geriatric populations who may require allergen-free or tailored formulations. Additionally, the rising prevalence of chronic diseases such as diabetes, cancer, and endocrine disorders is contributing to the need for customized treatment options. Compounding pharmacies play a crucial role in addressing drug shortages by providing alternative formulations of medications that are in limited supply. Their ability to create products that are not commercially available or customizable is shifting them from the background to the forefront of healthcare services. The growing recognition of these pharmacies is further supported by the increasing prevalence of chronic diseases, expanding the market as they demand long-term adherence to treatment protocols with precise dosages, making compounded medications a suitable solution.

The non-sterile segment led the market in 2024 and is anticipated to grow at a CAGR of 6.1% between 2025 and 2034. Non-sterile dosage forms include medicines taken orally, such as pills and liquids, or topical applications like creams and ointments. The rising demand for such dosage forms will boost the compounding pharmacies market and propel segmental growth. Additionally, non-sterile formulations are subject to less strict regulatory requirements, making them more accessible for 503A pharmacies operating under state pharmacy boards. As the incidence of chronic conditions, geriatric care needs, and lifestyle-related conditions continues to rise, the non-sterile segment is well-positioned to sustain its leading role in the U.S. compounding pharmacy landscape.

The oral segment dominated the market in 2024 with a market share of 33.1%. Increasing demand for oral compounded medications can be attributed to several benefits associated with the oral dosage form, such as self-administration, convenience, and pain-free. The availability of several medications in oral form, such as solid preparations that include capsules, tablets, powders, and liquid preparations like syrups and suspensions, compared to other dosage forms, fuels the segmental growth. Moreover, a higher preference for oral compounded medications in children and the geriatric population further drives the oral segment market growth.

Major players operating in the U.S. Compounding Pharmacies Industry include Triangle Compounding Pharmacies, Pavilion Compounding Pharmacy, Nephron Pharmaceuticals, McGuff Outsourcing Solutions, Institutional Pharmacy Solutions, Fagron, Dougherty's Pharmacy, Baxter International, Village Compounding Pharmacy, Wedgewood Pharmacy, Pencol Compounding Pharmacy, QuVa Pharma, Rx3 Compounding Pharmacy, B. Braun, and Harrow. These companies are adopting various strategies to strengthen their market position. They are investing in research and development to innovate and customize formulations effectively. Additionally, they are expanding their product portfolios to include a broader range of compounded medications. Strategic partnerships and collaborations are also being pursued to enhance distribution networks and improve market reach. Furthermore, these companies are focusing on compliance with regulatory standards to ensure the safety and efficacy of their compounded products. By implementing these strategies, they aim to meet the growing demand for personalized medications and address the challenges posed by drug shortages.

Table of Contents

142 Pages
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Data mining sources
1.3.1 Global
1.3.2 Regional/Country
1.4 Base estimates and calculations
1.4.1 Base year calculation
1.4.2 Key trends for market estimation
1.5 Primary research and validation
1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
2.2 Key market trends
2.2.1 Zonal
2.2.2 Pharmacy type
2.2.3 Sterility
2.2.4 Product
2.2.5 Compounding type
2.2.6 Therapeutic area
2.2.7 Application
2.3 CXO perspectives: strategic imperatives
2.3.1 Key decision points for industry executives
2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.1.1 Supplier landscape
3.1.2 Value addition at each stage
3.1.3 Factor affecting the value chain
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing geriatric population and improved longevity
3.2.1.2 Growing acceptance of personalized medicines in the U.S.
3.2.1.3 Increasing drug shortage
3.2.1.4 Convenience of using compounded drugs
3.2.1.5 Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women
3.2.2 Industry pitfalls and challenges
3.2.2.1 Issues related to safety standards of compounded drugs
3.2.2.2 Changing regulatory scenario
3.2.3 Market opportunities
3.2.3.1 Expanding veterinary compounding
3.2.3.2 Advancements in delivery technologies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement landscape
3.6 Innovative compounding technologies
3.6.1 Web-based quality management system
3.6.2 Digital tools
3.7 Future market trends
3.8 Consumer behaviour analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Pharmacy Type, 2021 – 2034 ($ Mn)
5.1 Key trends
5.2 503A
5.3 503B
Chapter 6 Market Estimates and Forecast, By Sterility, 2021 – 2034 ($ Mn)
6.1 Key trends
6.2 Sterile
6.3 Non-sterile
Chapter 7 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)
7.1 Key trends
7.2 Oral
7.2.1 Solid preparations
7.2.1.1 Tablets
7.2.1.2 Capsules
7.2.1.3 Granules
7.2.1.4 Powder
7.2.1.5 Other solid preparations
7.2.2 Liquid preparations
7.2.2.1 Solutions
7.2.2.2 Suspension
7.2.2.3 Emulsion
7.2.2.4 Syrup
7.2.2.5 Other liquid preparations
7.3 Topical
7.3.1 Ointments
7.3.2 Creams
7.3.3 Gels
7.3.4 Pastes
7.3.5 Other topical products
7.4 Rectal
7.4.1 Suppositories
7.4.2 Enema
7.4.3 Other rectal products
7.5 Parenteral
7.5.1 Large volume parenterals (LVPs)
7.5.2 Small volume parenterals (LVPs)
7.6 Nasal
7.7 Ophthalmic
7.8 Otic
Chapter 8 Market Estimates and Forecast, By Compounding Type, 2021 – 2034 ($ Mn)
8.1 Key trends
8.2 Pharmaceutical ingredient alteration (PIA)
8.3 Currently unavailable pharmaceutical manufacturing (CUPM)
8.4 Pharmaceutical dosage alteration (PDA)
8.5 Other compounding types
Chapter 9 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)
9.1 Key trends
9.2 Adult
9.3 Geriatric
9.4 Veterinary
9.5 Pediatric
Chapter 10 Market Estimates and Forecast, By Therapeutic Area, 2021 – 2034 ($ Mn)
10.1 Key trends
10.2 Pain management
10.3 Hormone replacement
10.4 Dermatology
10.5 Specialty drugs
10.6 Nutritional supplements
10.7 Other therapeutic areas
Chapter 11 Market Estimates and Forecast, By Zone, 2021 – 2034 ($ Mn)
11.1 Key trends
11.2 Northeast
11.2.1 Connecticut
11.2.2 Maine
11.2.3 Massachusetts
11.2.4 New Hampshire
11.2.5 Rhode Island
11.2.6 Vermont
11.2.7 New Jersey
11.2.8 New York
11.2.9 Pennsylvania
11.3 East North Central
11.3.1 Wisconsin
11.3.2 Michigan
11.3.3 Illinois
11.3.4 Indiana
11.3.5 Ohio
11.4 West North Central
11.4.1 North Dakota
11.4.2 South Dakota
11.4.3 Nebraska
11.4.4 Kansas
11.4.5 Minnesota
11.4.6 Iowa
11.4.7 Missouri
11.5 South Atlantic
11.5.1 Delaware
11.5.2 Maryland
11.5.3 District of Columbia
11.5.4 Virginia
11.5.5 West Virginia
11.5.6 North Carolina
11.5.7 South Carolina
11.5.8 Georgia
11.5.9 Florida
11.6 East South Central
11.6.1 Kentucky
11.6.2 Tennessee
11.6.3 Mississippi
11.6.4 Alabama
11.7 West South Central
11.7.1 Oklahoma
11.7.2 Texas
11.7.3 Arkansas
11.7.4 Louisiana
11.8 Mountain States
11.8.1 Idaho
11.8.2 Montana
11.8.3 Wyoming
11.8.4 Nevada
11.8.5 Utah
11.8.6 Colorado
11.8.7 Arizona
11.8.8 New Mexico
11.9 Pacific Central
11.9.1 California
11.9.2 Alaska
11.9.3 Hawaii
11.9.4 Oregon
11.9.5 Washington
Chapter 12 Company Profiles
12.1 Baxter International
12.2 B. Braun
12.3 Dougherty's Pharmacy
12.4 Fagron
12.5 Fresenius Kabi
12.6 Harrow
12.7 Institutional Pharmacy Solutions
12.8 ITC Compounding Pharmacy
12.9 McGuff Outsourcing Solutions
12.10 Nephron Pharmaceuticals
12.11 Pavilion Compounding Pharmacy
12.12 Pencol Compounding Pharmacy
12.13 QuVa Pharma
12.14 Rx3 Compounding Pharmacy
12.15 Triangle Compounding Pharmacies
12.16 Village Compounding Pharmacy
12.17 Wedgewood Pharmacy

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us